A U.S. judge on Monday rejected Bristol Myers Squibb’s bid to dismiss a $6.7 billion lawsuit claiming it cheated shareholders of the former Celgene by delaying federal approval for three drugs, including the cancer treatment Breyanzi, by specified deadlines.
While dismissing some claims, U.S. District Judge Jesse Furman in Manhattan said the plaintiff UMB Bank may pursue some claims on behalf of the shareholders, including for breach of contract.
(Reporting by Stempel in New York; Editing by Chris Reese)
Copyright 2025 Reuters. Click for restrictions.
Was this article valuable?
Here are more articles you may enjoy.
Standard Chartered Settles $2 Billion Iranian Sanction Suit in London 
Truckers Who Fail English Tests Get Pulled Off Roads in Trump Crackdown 
State Farm Sued Over Policies Backed by Distressed Insurer PHL 
Florida And East Coast Will See Big Losses From More Cat 5 Storms, Researchers Say 
Want to stay up to date?
Get the latest insurance news
sent straight to your inbox.